ArticleCritical care explorations2020
The Incidence of Propofol-Induced Hypertriglyceridemia and Identification of Associated Risk Factors.
Article in Critical care explorations, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Ciprofol Versus Propofol for Sedation in Gastrointestinal Endoscopy: A Systematic Review and Meta-Analysis in a Chinese Population.Drug design, development and therapy · 2025Pooled it
- Efficacy and Safety of Ciprofol for Sedation in Critically Ill Patients After Cardiac Surgery: A Single-Center, Prospective, Randomized Controlled Trial.Drug design, development and therapy · 2026Trial
- Trial
- Safety of Coadministration of Continuous Infusions of Propofol and Clevidipine: A Multi-Site Retrospective Analysis.Pharmacotherapy · 2026Article
- Hemodynamic Effects of Anesthetics, Sedatives, and Analgesics in the CICU: Clinical Decision Guidance.JACC. Advances · 2026Review
- Propofol-induced hypertriglyceridemia in critically ill trauma patients requiring nutrition therapy: A descriptive cohort study.JPEN. Journal of parenteral and enteral nutrition · 2026Article
- Ketogenic diet therapy for children with super-refractory status epilepticus in intensive care: International clinical practice recommendations.Epilepsia open · 2026Review
- Propofol and Hypertriglyceridemia in the ICU: A Systematic Review and Meta-Analysis of Recent Observational Data.Cureus · 2026Review
- Propofol-associated Hypertriglyceridemia: Development and Multicenter Validation of a Machine-Learning-Based Prediction Tool.Journal of intensive care medicine · 2025Article
- Propofol, Triglycerides, and Acute Pancreatitis: A Multicenter Epidemiologic Analysis.Annals of the American Thoracic Society · 2025Observational
- Food for Thought: Toward a More Nuanced Approach to Propofol-associated Hypertriglyceridemia.Annals of the American Thoracic Society · 2025Article
- Propofol-related biological alterations and incidence of propofol infusion syndrome in status epilepticus: a 10-year cohort study.Frontiers in neurology · 2025Article
- Acute Kidney Injury and Chronic Kidney Disease and Their Impacts on Prognosis among Patients with Severe COVID-19 Pneumonia: An Expert Center Case-Cohort Study.Journal of clinical medicine · 2024Article
- Triglyceride Concentrations and Their Relationship to Sedation Choice and Outcomes in Mechanically Ventilated Patients Receiving Propofol.Annals of the American Thoracic Society · 2023Observational
- A Comparison of the Effects of Prolonged Infusion of Propofol 2% and 1% During Total Intravenous Anaesthesia Using Target-Controlled Infusion Technique for Elective Neurosurgery.The Malaysian journal of medical sciences : MJMS · 2022Article
- Integrated omics analysis revealed theJournal of diabetes and metabolic disorders · 2022Article
- The Safety of Continuous Infusion Propofol in Mechanically Ventilated Adults With Coronavirus Disease 2019.The Annals of pharmacotherapy · 2022Article
- An intravenous anesthetic drug-propofol, influences the biological characteristics of malignant tumors and reshapes the tumor microenvironment: A narrative literature review.Frontiers in pharmacology · 2022Review
- Lipoprotein concentration in patients requiring extracorporeal membrane oxygenation.Scientific reports · 2021Article
- Combined pulse wave velocity and triglyceride-glucose index to discriminate large-artery atherosclerosis from small-vessel occlusion in acute ischaemic stroke: a single-centre retrospective study.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe objective of this study was to describe the incidence of propofol-induced hypertriglyceridemia and the risk factors associated with hypertriglyceridemia in mechanically ventilated ICU patients while receiving propofol.
designThis was a single-center case-control study.
settingBrigham and Women's Hospital, a tertiary academic medical center in Boston, MA. SUBJECTS: Adult ICU patients who received continuous infusion propofol for at least 24 hours from May 1, 2019, to December 31, 2019, were included. Patients were excluded if they were diagnosed with acute pancreatitis upon admission or did not have any serum triglyceride levels evaluated during propofol administration.
interventionsNone. MEASUREMENTS AND MAIN
resultsThe major outcome was the incidence and risk factors associated with the development of propofol-induced hypertriglyceridemia, defined as triglyceride level greater than or equal to 400 mg/dL. Minor outcomes included the prevalence of acute pancreatitis. A hybrid multivariate logistic regression analysis was used to evaluate the relation between individual risk factors and the dependent variable of hypertriglyceridemia. During the study period, 552 patients were evaluated for inclusion, of which 136 were included in the final analysis. A total of 38 patients (27.9%) developed hypertriglyceridemia with a median time to hypertriglyceridemia of 47 hours. The only significant independent risk factor for development of hypertriglyceridemia identified was the cumulative propofol dose (odds ratio, 1.04; 95% CI, 1.01-1.08;
conclusionsIn our analysis, approximately one third of patients developed hypertriglyceridemia with cumulative propofol dose identified as a significant predictor of the development of hypertriglyceridemia. Despite a high incidence of hypertriglyceridemia, a significant number of patients continued propofol therapy, and a relatively low prevalence of pancreatitis was observed. Future analyses are warranted to further investigate these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.